CSTONE PHARMA-B (02616) has released its interim results for the six months ended June 30, 2026, showing a substantial revenue increase of 314.75% to RMB 205 million. The company reported a loss of RMB 252 million for the period, representing a 6.62% reduction from the prior year, with a loss per share of RMB 0.17.

The revenue breakdown includes pharmaceutical sales of RMB 183 million from avapritinib, pralsetinib, and sugemalimab, along with licensing fee income of RMB 6.9 million and royalty income from sugemalimab totaling RMB 15 million. The significant revenue growth was primarily fueled by a notable surge in drug sales, particularly pralsetinib, which benefited from its inclusion in the National Reimbursement Drug List (NRDL) starting January 2026, driving a considerable increase in sales volume.

At the heart of our strategic approach lies the pursuit of sustainable growth through the global advancement of our pipeline 2.0, while optimizing the lifecycle value of our marketed products. This strategy is executed through a capital-efficient, asset-light model that concentrates internal resources on our core strengths: early-stage discovery, translational science, and clinical development. By leveraging partnerships with leading Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs), we maintain operational flexibility without compromising scientific rigor.

Our commercialization efforts are driven through strategic collaborations in key regional markets, expanding patient reach and boosting revenue growth while preserving a sharp focus on innovation. Moving forward, we will persist in enhancing our research and clinical capabilities, advancing high-potential assets into later-stage development, and implementing a tailored global partnership strategy to maximize the value of our commercial portfolio and pipeline.